Schering Corporation

Merck Sharp + Dohme Corp.

Walter Robert Bishop

Viyyoor Moopil Girijavallabhan

Ashit K Ganguly

Ronald J Doll

David L Cutler

Ming Liu

Loretta L Nielsen

Joseph J Catino

Paul Kirschimeier

Tattanahalli L Nagabhushan

Toshihiko Takeuchi

Linda Masat

Jonathan A Pachter

Yan Wang

Sumant Ramachandra

Chin-Yi Huang

Chao Bai Huang

Seema Kantak

Diana L Brassard

Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both in vivo and in vitro.

Fully human anti-VEGF antibodies and methods of using

The present invention provides combinations including a binding composition, such as an anti-IGFR1 antibody, in association with a chemotherapeutic agent. Methods for using the combinations to treat medical conditions, such as cancer, are also provided.

Anti-IGFR1 antibody therapeutic combinations

Methods are provided for treating proliferative diseases, especially cancers, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an antineoplastic agent and/or radiation therapy.

Methods for treating proliferative diseases

Methods are provided for treating cancer, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an additional Ras signaling pathway inhibitor to induce cancer cell death and tumor regression.

Methods of inducing cancer cell death and tumor regression

Method for treating proliferative diseases

Growing community of inventors

Pompton Plains, NJ, United States of America

Walter Robert Bishop